Amneal Takes Control Of AvKARE In US
Offers Access To Departments Of Defense And Veterans Affairs
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”
You may also be interested in...
With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.
Despite a couple of setbacks during Q2, Amneal has sustained continual growth across its business, particularly in the injectables space.
Amneal highlighted the benefits of a broad spread of generics and an increased shift towards complex products with high barriers to entry, as it reported generics sales growth in Q1 despite a tough operating environment for US generics.